BDBM225026 3-[6-{[(1r)-1- cyclobutylethyl]amino}-7- [(trans-4- methylcyclohexyl)methyl]-8- (1-pyridin-2-ylethyl)-7h- purin-2-yl]-1,2,4-oxadiazol- 5(4h)-one::US9540377, 22.71

SMILES CC(c1ccccn1)c1nc2nc(-c3noc(=O)[nH]3)nc(N[C@H](C)C3CCC3)c2n1C[C@H]1CC[C@H](C)CC1

InChI Key InChIKey=PPWJJTQTFXUAKH-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 225026   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 225026BDBM225026(US9540377, 22.71 | 3-[6-{[(1r)-1- cyclobutylethyl]...)
Affinity DataIC50: 6.49nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent